AKBA

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Dollar change -0.12
Percentage change -4.71	%

Peers: AMGN REGN VRTX BIIB GILD INCY ALKS NBIX AMRN EXEL

| Held by: VTI IWM XBI VXF IWN VTWO FESM IWC ITOT GSSC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.22	Insider Own	4.10%	Shs Outstand	261.64M	Perf Week	3.85%
Market Cap	638.21M	Forward P/E	-	EPS next Y	0.00	Insider Trans	-3.02%	Shs Float	251.86M	Perf Month	56.77%
Income	-45.31M	PEG	-	EPS next Q	-0.02	Inst Own	26.42%	Short Float	7.06%	Perf Quarter	15.71%
Sales	184.91M	P/S	3.45	EPS this Y	70.30%	Inst Trans	4.64%	Short Ratio	3.99	Perf Half Y	21.50%
Book/sh	0.09	P/B	25.86	EPS next Y	100.00%	ROA	-16.92%	Short Interest	17.77M	Perf Year	73.57%
Cash/sh	0.43	P/C	5.63	EPS next 5Y	-	ROE	-	52W Range	0.80 - 2.90	Perf YTD	27.89%
Dividend Est.	-	P/FCF	-	EPS past 5Y	32.58%	ROI	-21.93%	52W High	-16.21%	Beta	0.76
Dividend TTM	-	Quick Ratio	2.02	Sales past 5Y	-10.63%	Gross Margin	64.95%	52W Low	203.75%	ATR (14)	0.17
Dividend Ex-Date	-	Current Ratio	2.23	EPS Y/Y TTM	3.07%	Oper. Margin	-11.91%	RSI (14)	58.60	Volatility	8.59% 6.84%
Employees	181	Debt/Eq	8.39	Sales Y/Y TTM	-1.24%	Profit Margin	-24.51%	Recom	1.00	Target Price	7.30
Option/Short	Yes / Yes	LT Debt/Eq	7.41	EPS Q/Q	128.82%	Payout	-	Rel Volume	1.65	Prev Close	2.55
Sales Surprise	28.77%	EPS Surprise	178.95%	Sales Q/Q	75.84%	Earnings	May 08 BMO	Avg Volume	4.45M	Price	2.43
SMA20	6.72%	SMA50	16.88%	SMA200	35.04%	Trades		Volume	7,032,742	Change	-4.71%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-28-25	Initiated	Leerink Partners	Outperform	$7
Apr-01-25	Initiated	Jefferies	Buy	$6
Nov-29-23	Resumed	BTIG Research	Buy	$4
Aug-28-23	Upgrade	H.C. Wainwright	Neutral → Buy	$3.75
May-31-23	Upgrade	Piper Sandler	Neutral → Overweight	$2 → $4
Mar-31-22	Downgrade	Piper Sandler	Overweight → Neutral	$8 → $2
Mar-31-22	Downgrade	Needham	Buy → Hold
Mar-31-22	Downgrade	Mizuho	Buy → Neutral	$6 → $2
Mar-31-22	Downgrade	H.C. Wainwright	Buy → Neutral	$10 → $2
Mar-08-21	Initiated	Cantor Fitzgerald	Overweight	$8
Jan-29-21	Downgrade	JP Morgan	Neutral → Underweight
Nov-14-19	Reiterated	Needham	Buy	$18 → $15
Aug-06-19	Reiterated	H.C. Wainwright	Buy	$19 → $17
Jul-11-19	Reiterated	H.C. Wainwright	Buy	$23 → $21
May-02-19	Initiated	JP Morgan	Overweight	$12
Mar-20-19	Initiated	Citigroup	Neutral	$9
Sep-07-18	Resumed	Morgan Stanley	Equal-Weight
Aug-10-18	Reiterated	Needham	Buy	$20 → $18
Jun-06-18	Reiterated	H.C. Wainwright	Buy	$24 → $22
Dec-19-17	Initiated	Piper Jaffray	Overweight	$26

Show Previous Ratings

May-09-25 03:11AM	Akebia Therapeutics Inc (AKBA) Q1 2025 Earnings Call Highlights: Strong Revenue Performance and ... (GuruFocus.com)
May-08-25 08:15AM	Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates (Zacks) +6.50%
07:18AM	Akebia Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha) +6.03%
05:30PM	Loading…
05:30PM	Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
12:35PM	Akebia Q1 2025 Earnings Preview (Seeking Alpha)
10:44AM	Earnings To Watch: Akebia Therapeutics Inc (AKBA) Reports Q1 2025 Result (GuruFocus.com)
May-01-25 04:15PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
10:01AM	Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:00AM	Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights (GlobeNewswire)
Apr-10-25 08:56AM	Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock (Zacks) -8.82%
Apr-03-25 08:00AM	Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL , an Oral Therapy for Chronic Kidney Disease Licensed to Averoa (GlobeNewswire)
Apr-02-25 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-25-25 08:00AM	Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025 (GlobeNewswire)
01:01PM	Loading…
Mar-21-25 01:01PM	Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering (Zacks)
12:16PM	Accenture reports Q2 beat, Apple TV+ losing $1B annually: Morning Buzz (TipRanks)
09:19AM	Akebia's Valuation Looks Stretched Despite Auryxia's Loss Of Exclusivity (SeekingAlpha)
07:06AM	Why Akebia Therapeutics Inc. (AKBA) Went Down On Thursday? (InsiderMonkey)
Mar-20-25 05:00AM	Biggest stock movers Thursday: YY, FIVE, and more (SeekingAlpha) -28.17%
Mar-19-25 10:17PM	Akebia Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire) +11.37%
04:36PM	Is Akebia Therapeutics (AKBA) the Best Stock to Invest in for a Stock Market Game? (InsiderMonkey)
04:01PM	Akebia Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Mar-14-25 03:03AM	Akebia Therapeutics Inc (AKBA) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines ... (GuruFocus.com) +33.73%
Mar-13-25 11:32PM	Q4 2024 Akebia Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -12.44%
08:10AM	Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:09AM	Akebia Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo (vadadustat) Commercial Launch Progress Update (GlobeNewswire)
Mar-06-25 08:00AM	Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights (GlobeNewswire)
Mar-04-25 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:05PM	Loading…
Feb-04-25 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-14-25 08:28AM	Akebia announces multiple positive business updates (TipRanks)
Jan-13-25 08:00AM	Akebia Therapeutics Announces Multiple Positive Business Updates (PR Newswire) +6.86%
Jan-02-25 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-18-24 08:00AM	Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire) -5.88%
Dec-03-24 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
07:00AM	U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo (vadadustat) for CKD Patients on Dialysis (PR Newswire)
Nov-25-24 08:00AM	Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference (PR Newswire)
Nov-14-24 08:00AM	Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease (PR Newswire)
Nov-12-24 08:00AM	Akebia Therapeutics to Present at the Jefferies London Healthcare Conference (PR Newswire)
Nov-08-24 02:09AM	Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... (GuruFocus.com)
Nov-07-24 08:15AM	Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -6.75%
07:21AM	Akebia Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights (PR Newswire)
Nov-01-24 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +9.47%
08:00AM	Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights (PR Newswire)
Oct-22-24 08:00AM	Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo (vadadustat) for Patients on Dialysis (PR Newswire) +19.71%
Oct-15-24 08:00AM	Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024 (PR Newswire)
Oct-10-24 08:00AM	CMS Grants TDAPA Reimbursement for Vafseo (vadadustat) beginning January 1, 2025 (PR Newswire)
Oct-09-24 05:30PM	Akebia Therapeutics Inc (AKBA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Oct-07-24 08:00AM	Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo (vadadustat) for Patients on Dialysis (PR Newswire)
Oct-01-24 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Sep-05-24 08:00AM	Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo (vadadustat) for Patients on Dialysis (PR Newswire)
Sep-03-24 04:16PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -9.03%
Aug-26-24 10:45AM	Here's Why You Should Consider Buying Akebia (AKBA) Stock (Zacks)
08:00AM	Akebia Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
Aug-08-24 08:10AM	Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +7.21%
07:09AM	Akebia Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (PR Newswire)
Aug-02-24 08:00AM	Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights (PR Newswire)
Aug-01-24 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -6.52%
Jul-29-24 08:00AM	Akebia Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
Jul-11-24 06:00AM	Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo (vadadustat) Tablets (PR Newswire) +17.59%
Jul-01-24 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-27-24 08:18AM	Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference (PR Newswire) +6.98%
Jun-24-24 08:58AM	Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer (PR Newswire)
Jun-03-24 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-23-24 08:00AM	Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference (PR Newswire)
May-14-24 08:00AM	Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference (PR Newswire)
May-10-24 03:27PM	Akebia Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview (GuruFocus.com) -9.02%
03:06PM	Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 11:57AM	AKBA Stock Earnings: Akebia Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:10AM	Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:09AM	Akebia Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (PR Newswire)
May-02-24 08:30AM	Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights (PR Newswire)
May-01-24 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Apr-02-24 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.70%
Mar-28-24 11:50AM	FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia (Benzinga) -18.30%
07:06AM	Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD (Zacks)
Mar-27-24 08:26PM	Akebia Receives FDA Approval of Vafseo (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis (PR Newswire) +12.00%
Mar-26-24 01:12PM	Akebia Awaits FDA Word On Second Crack At Vadadustat (Barrons.com) -9.50%
Mar-14-24 09:53PM	AKBA Stock Earnings: Akebia Therapeutics Beats Revenue for Q4 2023 (InvestorPlace) +24.09%
05:51PM	Akebia Therapeutics Inc (AKBA) Reports Steady Revenue and a Profitable Quarter (GuruFocus.com)
05:30PM	Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4 (Zacks)
04:15PM	Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights (PR Newswire)
Mar-11-24 05:05PM	Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
Mar-01-24 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +8.23% -5.26%
Feb-02-24 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jan-30-24 08:00AM	Akebia Secures $55 Million Term Loan Financing (PR Newswire) -8.38%
Jan-09-24 08:30AM	Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer (PR Newswire)
Jan-02-24 04:30PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +7.87%
Dec-20-23 08:00AM	Akebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-01-23 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +7.48%
10:00AM	Top Penny Stocks for Q4 2023 (Investopedia)
Nov-20-23 08:00AM	Akebia Therapeutics to Present at Piper Sandler Healthcare Conference (PR Newswire)
Nov-09-23 11:32AM	Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.20%
Nov-08-23 10:05PM	Q3 2023 Akebia Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -11.93%
07:40AM	Akebia Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights (PR Newswire)

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Butler John P.	CEO and President	Mar 03 '25	Sale	1.83	46,409	84,928	2,557,921	Mar 04 05:05 PM
Burke Steven Keith	SVP, Chief Medical Officer	Mar 03 '25	Sale	1.83	7,144	13,074	809,090	Mar 04 05:04 PM
Burke Steven Keith	Officer	Mar 03 '25	Proposed Sale	1.83	7,144	13,086		Mar 03 05:39 PM
Butler John P.	Officer	Mar 03 '25	Proposed Sale	1.83	46,409	85,007		Mar 03 05:37 PM
Butler John P.	CEO and President	Feb 03 '25	Sale	2.10	144,250	302,925	2,604,330	Feb 04 05:54 PM
Burke Steven Keith	SVP, Chief Medical Officer	Feb 03 '25	Sale	2.10	50,506	106,063	816,234	Feb 04 05:53 PM
Malabre Richard C	SVP, Chief Accounting Officer	Feb 03 '25	Sale	2.10	30,202	63,424	280,248	Feb 04 05:52 PM
Grund Nicholas	Chief Commercial Officer	Feb 03 '25	Sale	2.10	55,621	116,804	442,579	Feb 04 05:51 PM
Grund Nicholas	Officer	Feb 03 '25	Proposed Sale	2.10	55,621	117,060		Feb 03 06:02 PM
Burke Steven Keith	Officer	Feb 03 '25	Proposed Sale	2.10	50,506	106,295		Feb 03 05:58 PM
Butler John P.	Officer	Feb 03 '25	Proposed Sale	2.10	144,250	303,589		Feb 03 05:50 PM
FRIESON RON	Director	Jan 17 '25	Option Exercise	0.45	20,100	9,045	93,800	Jan 22 04:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Akebia Therapeutics Inc

Upgrade your FINVIZ experience